Patents Assigned to Mercian Corporation
-
Patent number: 7060821Abstract: A compound represented by formula (I); a process for producing a compound (substance F-1490) of formula (I), wherein X represents —O— and R represents a hydroxyl group, by using a microorganism belonging to the genus Cunninghamella; and a Cunninghamella sp. F-1490 strain (FERM BP-8287) capable of producing the substance F-1490; and an osteoclast differentiation inhibitory agent containing as an active ingredient the compound represented by formula (I): wherein X represents —O— or —CH2—, and R represents a hydroxyl group when X represents —O—, or a hydrogen atom when X represents —CH2—.Type: GrantFiled: March 6, 2003Date of Patent: June 13, 2006Assignees: Mercian Corporation, Zaidan Hojin Biseibutsu Kagaku Kenkyu KaiInventors: Hiroyuki Kumagai, Tomohiro Sameshima, Motoko Matsufuji, Naoto Kawamura, Kunio Isshiki, Hiroyuki Inoue, Tetsuya Someno, Masaaki Ishizuka, Tomio Takeuchi
-
Patent number: 7026352Abstract: The present invention provides a novel bioactive substance having an antitumor activity and a process for producing it, and a medical use thereof. Namely, it provides a 12-membered ring macrolide compound represented by the following formula obtained from the incubation solution of Streptomyces sp. Mer.Type: GrantFiled: February 1, 2002Date of Patent: April 11, 2006Assignees: Mercian Corporation, Eisai Co., Ltd.Inventors: Yoshiharu Mizui, Takashi Sakai, Satoshi Yamamoto, Keisuke Komeda, Masanori Fujita, Akifumi Okuda, Kumiko Kishi, Jun Niijima, Mitsuo Nagai, Kiyoshi Okamoto, Masao Iwata, Yoshihiko Kotake, Toshimitsu Uenaka, Naoki Asai, Motoko Matsufuji, Tomohiro Sameshima, Naoto Kawamura, Kazuyuki Dobashi, Takashi Nakashima, Masashi Yoshida, Toshio Tsuchida, Susumu Takeda, Tomonari Yamada, Koji Norihisa, Takao Yamori
-
Patent number: 7022502Abstract: A process for the production of L-pipecolic acid which comprises the step of reducing delta-1-piperideine-6-carboxylic acid by the use of pyrroline-5-carboxylate reductase. The delta-1-piperideine-6-carboxylic acid is obtained by the step of converting L-lysine by the use of lysine 6-aminotransferase encoded by a gene of Flavobacterium lutescens. The steps of reducing delta-1-piperideine-6-carboxylic acid and the converting of L-lysine into L-pipecolic acid by the use of lysine 6-aminotransferase are carried out by using a bacterium transformed with a gene encoding lysine 6-aminotransferase wherein such bacterium comprises pyrroline-5-carboxylate reductase encoded by a gene of Escherichia coli or a coryneform bacterium. A recombinant bacterium which can be used in this production process is also provided. Thus, the present invention can provide an efficient biological process for the production of L-pipecolic acid (or 2-piperidinecarboxylic acid).Type: GrantFiled: December 22, 2000Date of Patent: April 4, 2006Assignee: Mercian CorporationInventors: Tadashi Fujii, Yasuhide Aritoku, Manabu Mukaihara, Takao Narita, Hitosi Agematu, Kunio Isshiki
-
Publication number: 20060009439Abstract: The present invention relates to a compound represented by the formula (I): (wherein, R3, R6, R7 and R21 are the same as or different from one another and each represents a hydroxyl group etc.), a pharmacologically acceptable salt thereof or a hydrate of them. The compound (I) of the present invention suppresses angiogenesis, in particular, suppresses VEGF production in a hypoxic condition and is useful as a therapeutic agent for treating solid cancer.Type: ApplicationFiled: May 29, 2003Publication date: January 12, 2006Applicants: MERCIAN CORPORATION, Eisai Co., Ltd.Inventors: Yoshihiko Kotake, Jun Niijima, Yoshio Fukuda, Mitsuo Nagai, Regina Kanada, Takashi Nakashima, Masahi Yoshida, Toshio Tsuchida
-
Publication number: 20050131061Abstract: Compounds represented by formula (I) below; a process for producing the compounds by culturing a microorganism belonging to the genus Aspergillus and isolating the above-mentioned compounds from the culture; an angiogenesis inhibitory agent containing as an active ingredient the compounds; and an Aspergillus sp. F-1491 (FERM BP-8288) strain capable of producing the compounds. In formula (I), R represents a methyl group or an ethyl group, R1 represents a hydrogen atom, a chlorine atom, a hydroxyl group or a methoxy group, R2 represents a hydroxyl group, or R1 and R2 taken together form an epoxy ring structure.Type: ApplicationFiled: March 6, 2003Publication date: June 16, 2005Applicants: Mercian Corporation, Zaidan Hojin Biseibutsu Kagaku Kenkyu KaiInventors: Hiroyuki Kumagai, Tomohiro Sameshima, Motoko Matsufuji, Naoto Kawamura, Tetsuya Someno, Masaaki Ishiduka, Tomio Takeuchi
-
Publication number: 20050124050Abstract: A compound represented by formula (I); a process for producing a compound (substance F-1490) of formula (I), wherein X represents —O— and R represents a hydroxyl group, by using a microorganism belonging to the genus Cunninghamella; and a Cunninghamella sp. F-1490 strain (FERM BP-8287) capable of producing the substance F-1490; and an osteoclast differentiation inhibitory agent containing as an active ingredient the compound represented by formula (I): wherein X represents —O— or —CH2—, and R represents a hydroxyl group when X represents —O—, or a hydrogen atom when X represents —CH2—.Type: ApplicationFiled: March 6, 2003Publication date: June 9, 2005Applicant: Mercian Corporation and Zaidan Hojin Biseibutsu Kagaku Kenkyu KaiInventors: Hiroyuki Kumagai, Tomohiro Sameshima, Motoko Matsufuji, Naoto Kawamura, Kunio Isshiki, Hiroyuki Inoue, Tetsuya Someno, Masaaki Sihizuka, Tomio Takeuchi
-
Patent number: 6900340Abstract: A method of preparing optically active isocoumarin-3-yl-acetic acid derivatives represented by Formula (I): wherein a specific isocoumarin-ketene derivative is subjected to an addition reaction with an optically active alcohol, and then the ester thus obtained is subjected to a hydrolysis reaction. An intermediate for synthesis used therein. A method of preparing isocoumarin-3-yl-acetic acid derivatives represented by Formula (III): wherein a specific isocoumarin derivative is subjected to an addition reaction with carbon monoxide and oxygen in the presence of a transition metal catalyst. An intermediate for synthesis used therein.Type: GrantFiled: February 1, 2002Date of Patent: May 31, 2005Assignee: Mercian CorporationInventor: Masaya Nakata
-
Patent number: 6890746Abstract: Provided are an isolated gene capable of participating in the production of L-homoglutamic acid, and a production system of L-homoglutamic acid by using this gene. The gene is derived from the genome of Flavobacterium lutescens.Type: GrantFiled: August 4, 1999Date of Patent: May 10, 2005Assignee: Mercian CorporationInventors: Tadashi Fujii, Takao Narita, Kuniho Nakata, Hitosi Agematu, Hiroshi Tsunekawa, Kunio Isshiki, Takeo Yoshioka
-
Patent number: 6747012Abstract: Disclosed are a crystalline form of anthracycline antibiotic having specific characteristic 2&thgr; values as measured by the X-ray diffraction method, and a process for producing the crystalline form. This process comprises the step of crystallization involving the combined use of a specific poor solvent for the antibiotic and a good solvent thereof. This crystalline form has excellent chemical and physical properties.Type: GrantFiled: June 1, 2000Date of Patent: June 8, 2004Assignee: Mercian CorporationInventors: Osamu Johdo, Kiyotomo Nakamura, Takeo Yoshioka
-
Patent number: 6653455Abstract: Disclosed are a crystallizing method of doxorubicin hydrochloride from a doxorubicin hydrochloride-containing solution, particularly a method for carrying out the crystallization under a condition of 40° C. or higher, and a doxorubicin hydrochloride crystalline aggregate having particularly an excellent solubility in water.Type: GrantFiled: April 13, 2001Date of Patent: November 25, 2003Assignee: Mercian CorporationInventors: Osamu Johdo, Takuma Nakao, Takeo Yoshioka
-
Patent number: 6645996Abstract: The present invention provides a novel bioactive substance having an antiangiogenic effect. The chemical compound represented by the formula (1) (wherein, R1 represents hydrogen atom, aldehyde group or a lower acyl group, R2 and R3 are the same as or different from each other and represent hydrogen atom or a lower alkoxy group or are combined to represent oxygen atom, R4 represents a lower alkyl group and R5 represents hydrogen atom or a lower alkyl group, provided that compounds in which R1 is aldehyde group, R2 and R3are different from each other and are hydrogen atom or methoxy group, R4 is ethyl group and R5 is hydrogen atom are excluded), a salt thereof or a hydrate thereof was isolated from the culture broth of genus Streptomyces and the structure thereof was analyzed.Type: GrantFiled: November 17, 2000Date of Patent: November 11, 2003Assignee: Mercian Corporation and Eisai Co., Ltd.Inventors: Toshiaki Wakabayashi, Rena Kawase, Nobuaki Naruse, Masanori Fujita, Tomohiro Sameshima, Yoshio Watanabe, Kazuyuki Dobashi, Yasuhiro Funahashi, Taro Semba
-
Patent number: 6589981Abstract: A method for enhancing the efficacy of chemotherapy and/or radiation in the treatment of cancer in animals, particularly humans, is provided wherein certain isocoumarin derivatives which exhibit unique radiosensitization activity and/or chemopotentiation properties are employed in a combination treatment with ionizing radiation and/or chemotherapy.Type: GrantFiled: February 27, 2001Date of Patent: July 8, 2003Assignees: ILEX Oncology, Inc., Mercian CorporationInventors: Corinne L. Reimer, Naoki Agata, Tomio Takeuchi, Hiroyuki Kumagai, Takeo Yoshioka, Masaaki Ishizuka, Donald W. Kufe, Ralph R. Weichselbaum
-
Patent number: 6566394Abstract: Salicylamide derivatives represented by formulae (1a) and (1b); intermediates in the production thereof; a process for producing the same; and drugs containing the same as the active ingredient. The salicylamide derivatives represented by formulae (1a) and (1b) are useful as anti-inflammatory agents and immunosuppressive agents which exert an effect of inhibiting the activation of NF-&kgr;B with little side effects.Type: GrantFiled: May 30, 2002Date of Patent: May 20, 2003Assignees: Mercian Corporation, Zaidan Hojin Biseibutsu Kagaku Kenkyu KaiInventors: Tomio Takeuchi, Kazuo Umezawa, Sakino To-E, Naoki Matsumoto, Tsutomu Sawa, Takeo Yoshioka, Naoki Agata, Shin-ichi Hirano, Kunio Isshiki
-
Patent number: 6548695Abstract: Provided is a process for producing an isocoumarin-3-yl-acetic acid derivative, characterized by reacting a homophthalic acid derivative represented by a formula: (wherein Rc, R2 and R are mainly protecting groups) with a malonic acid derivating represented by a formula: (wherein R is an organic group including a lower alkyl group; R3 is a protecting group for a carboxyl group; and X is a halogen atom or a —OM group (wherein M is alkaline metal or alkaline earth metal)). According to the above process, various isocoumarin-3-yl-acetic acid derivatives can efficiently be provided.Type: GrantFiled: April 11, 2002Date of Patent: April 15, 2003Assignees: Mercian Corporation, Zaidan Hojin Biseibutsu Kagaku Kenkyu KaiInventors: Toshio Tsuchida, Hazuki Nagai, Takashi Nakashima, Masashi Yoshida, Kaname Konuki, Asako Kuroda, Kunio Isshiki, Tomio Takeuchi
-
Patent number: 6426420Abstract: Provided is a process for producing an isocoumarin-3-yl-acetic acid derivative, characterized by reacting a homophthalic acid derivative represented by a formula: (wherein Rc, R2 and R are mainly protecting groups) with a malonic acid derivating represented by a formula: (wherein R is an organic group including a lower alkyl group; R3 is a protecting group for a carboxyl group; and X is a halogen atom or a —OM group (wherein M is alkaline metal or alkaline earth metal)). According to the above process, various isocoumarin-3-yl-acetic acid derivatives can efficiently be provided.Type: GrantFiled: July 5, 2000Date of Patent: July 30, 2002Assignees: Mercian Corporation, Zaidan Hojin Biseibutsu Kagaku Kenkyu KaiInventors: Toshio Tsuchida, Hazuki Nagai, Takashi Nakashima, Masashi Yoshida, Kaname Konuki, Asako Kuroda, Kunio Isshiki, Tomio Takeuchi
-
Patent number: 6410759Abstract: A method for preparing at least one hydroxycholesterol chosen from the group consisting of 25-hydroxycholesterol, 17,25-dihydroxycholesterol and 25,26-dihydroxycholesterol by biological hydroxylation of cholesterol, and the aforementioned dihydroxycholesterols. In the above biological hydroxylation, a microorganism is used which has the abovementioned hydroxylation capacity and which belongs to the genus Amycolata and the genus Sphingomonas.Type: GrantFiled: July 31, 2000Date of Patent: June 25, 2002Assignee: Mercian CorporationInventors: Koji Takeda, Tadashi Terasawa, Kazuyuki Dobashi, Takeo Yoshioka
-
Patent number: 6388058Abstract: The present invention relates to a method in which daunomycin is eluted from a hydrophobic porous synthetic resin carrier onto which daunomycin is adsorbed from crude daunomycin with a buffered aqueous solution containing a water-miscible organic solvent to recover purified daunomycin. Daunomycin (daunorubicin) is purified efficiently.Type: GrantFiled: February 25, 2000Date of Patent: May 14, 2002Assignee: Mercian CorporationInventors: Osamu Johdo, Konomi Iguchi, Takeo Yoshioka
-
Patent number: 6361987Abstract: This invention provides DNA fragments for efficiently preparing a protein having asymmetric hydrolase activity for 4-substituted 1,4-dihydropyridine derivatives, transformants obtained by using such a DNA fragment, and a process for preparing the aforesaid enzyme. Specifically, an isolated gene derived from the chromosome of Streptomyces viridosporus and encoding a protein having asymmetric hydrolase activity for 4-substituted 1,4-dihydropyridine derivatives, plasmids having the aforesaid gene integrated thereinto, transformants obtained by using such a plasmid, and a process for preparing the aforesaid enzyme by using such a transformant are disclosed. A process for the enzymatic conversion of 4-substituted 1,4-dihydropyridine derivatives by using the aforesaid enzyme is also disclosed.Type: GrantFiled: February 28, 2000Date of Patent: March 26, 2002Assignee: Mercian CorporationInventors: Akira Arisawa, Motoko Matsufuji, Takurou Tsuruta, Kazuyuki Dobashi, Takashi Nakashima, Kunio Isshiki, Takeo Yoshioka
-
Patent number: 6146844Abstract: A method for preparing at least one hydroxycholesterol chosen from the group consisting of 25-hydroxycholesterol, 17,25-dihydroxycholesterol and 25,26-dihydroxycholesterol by biological hydroxylation of cholesterol, and the aforementioned dihydroxycholesterols. In the above biological hydroxylation, a microorganism is used which has the abovementioned hydroxylation capacity and which belongs to the genus Amycolata and the genus Sphingomonas.Type: GrantFiled: February 26, 1998Date of Patent: November 14, 2000Assignee: Mercian CorporationInventors: Koji Takeda, Tadashi Terasawa, Kazuyuki Dobashi, Takeo Yoshioka
-
Patent number: 6143541Abstract: This invention provides DNA fragments for efficiently preparing a protein having asymmetric hydrolase activity for 4-substituted 1,4-dihydropyridine derivatives, transformants obtained by using such a DNA fragment, and a process for preparing the aforesaid enzyme. Specifically, an isolated gene derived from the chromosome of Streptomyces viridosporus and encoding a protein having asymmetric hydrolase activity for 4-substituted 1,4-dihydropyridine derivatives, plasmids having the aforesaid gene integrated thereinto, transformants obtained by using such a plasmid, and a process for preparing the aforesaid enzyme by using such a transformant are disclosed. A process for the enzymatic conversion of 4-substituted 1,4-dihydropyridine derivatives by using the aforesaid enzyme is also disclosed.Type: GrantFiled: January 30, 1998Date of Patent: November 7, 2000Assignee: Mercian CorporationInventors: Akira Arisawa, Motoko Matsufuji, Takurou Tsuruta, Kazuyuki Dobashi, Takashi Nakashima, Kunio Isshiki, Takeo Yoshioka